The companies will work with investigators to share the results with the scientific community
Opinion granted based on positive disease-free survival results from the Phase 3 KEYNOTE-091 trial
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
Honeywell Solstice Air is a hydrofluoroolefin (HFO) propellant in clinical development today for pMDIs
Combination creates an integrated provider of drug development and regulatory consulting services serving a complementary client base
Ryan has nearly 20 years of global legal and IP expertise in the pharmaceutical industry
Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease
Subscribe To Our Newsletter & Stay Updated
